Daniel Stuart Farb - 28 Dec 2022 Form 4 Insider Report for PharmaCyte Biotech, Inc. (PMCB)

Role
Director
Signature
/s/ Daniel Stuart Farb
Issuer symbol
PMCB
Transactions as of
28 Dec 2022
Net transactions value
$0
Form type
4
Filing time
30 Dec 2022, 15:05:56 UTC
Previous filing
23 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMCB Stock Option (Right to Buy) Award $0 +125,000 $0.000000 125,000 28 Dec 2022 Common Stock 125,000 $2.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel Stuart Farb is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Issuer's board of directors on November 14, 2022, subject to stockholder approval of the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the "2022 Plan"), under which the option was granted. The Issuer's stockholders approved the 2022 Plan on December 28, 2022.